Choosing the Best Treatment Regimen in Multiple Myeloma: Episode 2 – the Relapsed/Refractory Setting

Episode 2 October 21, 2021 00:24:56
Choosing the Best Treatment Regimen in Multiple Myeloma: Episode 2 – the Relapsed/Refractory Setting
COR2ED Medical Education
Choosing the Best Treatment Regimen in Multiple Myeloma: Episode 2 – the Relapsed/Refractory Setting

Show Notes

In this medical education podcast series, myeloma experts Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford University Hospitals in London, UK) and Dr. Joshua Richter (Assistant Professor of Medicine and Director of Myeloma at the Tisch Cancer Institute at the Icahn School of Medicine and the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York, USA) discuss their experience and views on choosing the best treatment every time in multiple myeloma.

In this second episode, Dr. Richter and Dr. Ramasamy explore how to select the best treatment approach in the second-line setting and beyond. Firstly, they discuss at what point they consider a patient to actually be in relapse. They both believe that it’s important to stay on top of this incurable illness and act when there is a suspicion of relapse. However, the need to treat must be balanced with quality of life. They also take potential enrolment into a clinical trial into account in the treatment decision.

The decision on which treatment option to select in the second line and beyond mostly depends on refractoriness to other drugs. With an increasing number of novel treatment options becoming available, choosing a regimen that does not contain a drug the patient is refractory to is becoming easier. Dr. Richter and Dr. Ramasamy discuss the challenges around these treatment decisions.

Furthermore, they share their experiences with CAR-T and other T cell redirection therapies, and when to use it in the treatment sequence. The speakers conclude with a look into the future of myeloma treatment.

Other Episodes

Episode 2

February 07, 2022 00:25:10
Episode Cover

Inhibidores de PARP en cáncer de próstata: lo que las enfermeras necesitan saber

COR2ED Educación Médica: Pablo Peinado, coordinador de Enfermería de Investigación, y la Dra. Elena Castro, oncóloga médica, quienes trabajan en el Hospital Universitario Virgen de la Victoria de Málaga en España, discuten 'El potencial de los inhibidores de PARP en el cáncer de próstata: Lo que las enfermeras necesitan para saber'. En este podcast, los expertos analizan los inhibidores de PARP (PARPi), cómo funcionan y los datos clave de los ensayos de registro de rucaparib y olaparib, TRITON2 y PROfound. También discuten cómo seleccionar PARPi para sus pacientes con cáncer de próstata y dónde encajan en la secuencia general del tratamiento. Pablo brinda información sobre la comunicación con los pacientes y los tipos de preguntas e inquietudes que suelen tener en relación con las pruebas genéticas y el tratamiento con PARPi. Además, también analizan los PARPi que se encuentran actualmente en la última etapa de desarrollo, como niraparib y talazoparib, así como el posible uso futuro de los PARPi en combinación con inmunoterapias o inhibidores de la vía del receptor de andrógenos. ...



December 02, 2021 00:29:56
Episode Cover

VEGFR-TKIs alone or in combination with immune checkpoint inhibitors in clinical practice for the treatment of HCC

In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or unresectable HCC and explain the immunomodulation rationale to combine it with immune checkpoint inhibitor. Combination approach has been validated recently with the atezolizumab+bevacizumab combination being the new standard of care in 1L setting for advanced HCC patients. In the context of advanced HCC, both experts share their view about the dosing approach with VEGFR-TKI and provide insight to handle the dosing when combining with PD-1 inhibitor. Both experts reiterate that biomarkers are urgently needed in HCC and summarize the current stratification of patients used to predict the response with VEGFR-TKI monotherapy or in immunotherapy combination. Finally, they emphasize that pre-habilitation of HCC patients is key to make the HCC patient fit for the best available treatment option. ...


Episode 1

February 28, 2022 00:13:11
Episode Cover

Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively. ...